Carboplatin versus cisplatin

J. B. Vermorken, W. W. Ten Bokkel Huinink, E. A. Eisenhauer, G. Favalli, D. Belpomme, P. F. Conte, S. B. Kaye

Research output: Contribution to journalArticlepeer-review


Background: Since the introduction of the second generation platinum compound carboplatin, debate has taken place about whether this analogue can replace cisplatin in combination chemotherapy regimens for the treatment of ovarian cancer patients. Materials and methods: In the present review the pharmacologic characteristics of carboplatin and cisplatin and the results of comparative studies are described. Results: Many of the trials performed comparing carboplatin with cisplatin, either as single agent first-line therapy or in combination chemotherapy suggest equivalent results. However, most of these trials are characterized by an inadequate patient number to detect small but important differences, inadequate carboplatin doses, ratios

Original languageEnglish
JournalAnnals of Oncology
Issue numberSUPPL. 4
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Carboplatin versus cisplatin'. Together they form a unique fingerprint.

Cite this